The reporter learned from Boehringer Ingelheim that the company expects that by 2030, 20 new products or new indications in the field of human medication will be approved in China, covering the fields of cardiac and renal metabolism, respiratory diseases, oncology, ophthalmology, and mental health; in the field of animal health, it is expected that nearly 10 new products or new indications will be approved. Chen Wenhan, general manager of Boehringer Ingelheim's Greater China Human Drugs Division, explained that the company will continue to expand localized production in China. The Shanghai Zhangjiang Pharmaceutical Production Base has now become an important supply hub in the Asia-Pacific region. In the third quarter of this year, the company plans to launch localized production of Boyouwei, an innovative drug for pulmonary fibrosis, at this base. Previously, Boehringer Ingelheim had already initiated a plan for the localized production of the diabetes drug O'Downing in China. The company said it will continue to expand its local production and packaging network in China in the future.

The reporter learned from Boehringer Ingelheim that the company expects that by 2030, 20 new products or new indications in the field of human medication will be approved in China, covering the fields of cardiac and renal metabolism, respiratory diseases, oncology, ophthalmology, and mental health; in the field of animal health, it is expected that nearly 10 new products or new indications will be approved. Chen Wenhan, general manager of Boehringer Ingelheim's Greater China Human Drugs Division, explained that the company will continue to expand localized production in China. The Shanghai Zhangjiang Pharmaceutical Production Base has now become an important supply hub in the Asia-Pacific region. In the third quarter of this year, the company plans to launch localized production of Boyouwei, an innovative drug for pulmonary fibrosis, at this base. Previously, Boehringer Ingelheim had already initiated a plan for the localized production of the diabetes drug O'Downing in China. The company said it will continue to expand its local production and packaging network in China in the future.